the National Cures Agenda

Tomorrow's Cures Today

Foundation

"Justice will not be served until those who are unaffected are as outraged as those who are" - Benjamin Franklin


"Even as health care is being completely reinvented in response to unsustainable increases in costs, the drug development paradigm has remained essentially unchanged" - PriceWaterhouseCooper, Beyond Borders - 2012

"We have to put patients at the center of the system.  There are 7,000 known diseases.  We have treatments for only 500 of them.  We have work to do."  - Margaret Anderson, Executive Director - FasterCures 

"We do our utmost to make sure patients in urgent need can choose earlier access to the latest promising treatments that might extend or even save their lives" - www.MyTomorrows.com

"While the FDA currently has the legal power to create its own conditional approval process, it has little political latitude to do so.  For this reason we believe Congress must create clear standards for such a pathway." Avik Roy - Senior Fellow Manhattan Institute - "Stifling Cures: The True Cost of Lengthy Clinical Drug Trials"

Gregory Conko
Gregory Conko is a Senior Fellow at the Competitive Enterprise Institute. His research focuses on issues of food and pharmaceutical safety regulations, and on the general treatment of health risks in public policy.  His writings have appeared in the Wall Street Journal, Los Angles Times, and Politics and the Life Sciences.  He is a board member for the American Council of Science and Health.  Conko received his JD from George Mason University with highest honors and served as Articles Editor of the Journal of Law, Economic & Policy. 

Bartley J Madden
Bartley J Madden retired as a Managing Director of Credit Suisse/Holt after a career in money management and investment research which included the development of CFROI valuation model still used today by money management firms around the world. Madden, currently an independent researcher, focuses on knowledge building and wealth creation and the application of systems-thinking in public policy.  He is author to Free To Choose Medicine, the foundation of Tomorrow's Cures Today.

Susan Dudley

Susan Dudley is Director of George Washington University's Regulatory Studies Center and Research Professor at the Trachtenberg School of Public Policy and Public Administration. Dudley founded the Center in 2009, served in the US Office of Information and Regulatory Affairs and Office of Management and Budget from 2007 to 2009, and also served as an economist at the Environmental Protection Agency and the Futures Trading Commission.

Vernon Smith
Vernon Smith is a professor of economics at Chapman University's Argyros School of Business and Economics and Law in Orange, California, a research scholar at George Mason University Interdisciplinary Center for Economic Science, and Fellow of the Mecatus Center in Arlington, VA.  Smith shares the 2002 Nobel Memorial Prize in Economic Science with Daniel Kahnerman.

BUILD ADVOCACY

We foster regulatory environments compatible with the advancement of medical technologies and biomedical informatics within competitive approval processes.

PROVIDE SOLUTIONS 

We provide policy proposals needed to lower drug development costs and provide more high quality information to greatly accelerate the discovery and production of new medicines.

CONVENE EXPERTS

Tomorrow's Cures Today seeks to be part of a coalition aimed at a comprehensive legislative agenda that addresses the systemic barriers that impede the development of cures.

Board of Advisors

National Agenda

  • Restructure "expanded access" provisions (compassionate use), allowing patients under the guidance of a physician to access drugs that have passed FDA Phase I and at least one Phase II trials without seeking the government's permission.
  • Create an alternative "initial approval" allowing drug companies to legally provide investigational new drugs to patients under a private "hold harmless" contract.
  • Enable reimbursement from payers and government agencies
  • Address information collection, intellectual property rights, data exclusivity for promising new drugs, including drugs being tested for uses not on their labels (off-label).
  • Create big data systems that provide patient-outcomes and personal medical information to allow doctors to better evaluate the safety and effectiveness of drugs in real-use.

 

Common Beliefs